FDA Fast-Tracks Two New Merck Drugs with Billion-Dollar Potential
Published on: Dec. 18, 2025, 3:15 a.m. | Source: Devdiscourse
The FDA is expediting the review of Merck's experimental drugs, enlicitide decanoate and sacituzumab tirumotecan. These drugs are part of a new priority voucher program aiming to shorten review times from 10-12 months to one or two months for drugs of significant public health impact.
